BlackRock Investment Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

BlackRock Investment Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$8K	Hold	2,889	–	–	﹤0.01%	3679
2016 Q3	$17K	Buy	2,889 +307	+12%	+$1.08K	﹤0.01%	3411
2016 Q2	$8K	Sell	2,582 -50,335	-95%	-$207K	﹤0.01%	3736
2016 Q1	$284K	Buy	52,917 +956	+2%	+$6.03K	﹤0.01%	3089
2015 Q4	$617K	Buy	51,961 +75	+0.1%	+$858	﹤0.01%	2908
2015 Q3	$426K	Sell	51,886 -1,311	-2%	-$15.1K	﹤0.01%	3085
2015 Q2	$742K	Buy	53,197 +42,739	+409%	+$784K	﹤0.01%	2971
2015 Q1	$251K	Sell	10,458 -237	-2%	-$5.33K	﹤0.01%	3175
2014 Q4	$176K	Hold	10,695	–	–	﹤0.01%	3267
2014 Q3	$136K	Sell	10,695 -65	-0.6%	-$980	﹤0.01%	3281
2014 Q2	$243K	Buy	10,760 +916	+9%	+$16.6K	﹤0.01%	3218
2014 Q1	$278K	Buy	+9,844	New	+$366K	﹤0.01%	3183

Other funds holding DRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BlackRock Investment Management's DRNA Position: Q4 2016 in Review

BlackRock Investment Management held its Dicerna Pharmaceuticals, Inc. (DRNA) position steady in Q4 2016 at 2,889 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #3679.

BlackRock Investment Management first reported a position in DRNA in Q1 2014 and has held it in 12 quarters since. The position peaked at $742K in Q2 2015. 50 funds tracked by Wall St. Rank hold DRNA as of Q4 2016.

BlackRock Investment Management held 2,889 shares of Dicerna Pharmaceuticals, Inc. worth $8K as of Q4 2016.
BlackRock Investment Management left its Dicerna Pharmaceuticals, Inc. share count unchanged in Q4 2016.
Dicerna Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3679 holding.
BlackRock Investment Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2014 and has held it in 12 quarters since.
BlackRock Investment Management's Dicerna Pharmaceuticals, Inc. position peaked at $742K in Q2 2015.
50 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.